This book examines patent law and policy in biotechnology across the full lifecycle of the patent, focusing on the patent bargain and the public interest. It considers the central issues of how to strike an effective balance of rights, and whether public interest is adequately safeguarded - two issues that are particularly important in areas of rapidly emerging technology. Expert contributors are brought together to explore patent eligibility in biotechnology, focusing on the fields of precision medicine, biofabrication and non-invasive prenatal testing. Chapters also explore the construction and coherence of exceptions to patentability,an examination of FRAND licensing in the context of the internet of medical things, and the possibility of using licensing to encourage or ensure the ethical use of patented technologies. With its carefully constructed analysis, this book will be an excellent resource for academic researchers, and students, in the fields of biotechnology law, pharmaceutical law and intellectual property law. It will also be useful for legal practitioners and policymakers, as well as charitable bodies and non-governmental organisations.

Now with a new afterword covering the months-long landmark trials of Elizabeth Holmes and Sunny Balwani. ‘I couldn’t put down this thriller . . . the perfect book to read by the fire this winter.’ Bill Gates Winner of the Financial Times/McKinsey Business Book of the Year Award 2018 The riveting true story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup founded by Elizabeth Holmes, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup ‘unicorn’ promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: the technology didn’t work. In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley. ‘Chilling . . . Reads like a West Coast version of All the President’s Men.’ New York Times Book Review

Biotechnology is a field that inspires complex legal and ethical debates on an international scale. Taking a fresh approach to the subject, Matthias Herdegen provides a comprehensive assessment of the regulation of biotechnology processes and products from an international and comparative perspective. Herdegen explores how regulatory approaches to controversial issues such as: stem cell research and cloning and gene therapy differ across jurisdictions due to conflicting values and risk perceptions. The book goes on to examine how international regulatory instruments aim to address these conflicting perspectives and provide judgments based on broad international consensus. Chapters explore the interaction between biotechnology and different fields of law including: human rights, intellectual property, trade law and environmental law. In doing so, a number of complex issues are raised such as the need to balance commercial interests with socio-cultural considerations and the need to ensure respect for human dignity in the pursuit of biomedical research. Providing a concise and accessible guide to a complex field of international law, this book will be of great value to those researching the law and regulation of biotechnology, biomedicine and biodiversity both within the EU and on an international scale. The book will also be a useful resource for practicing lawyers as it includes sources from a diverse range of legal systems and analyses relevant decisions by international adjudicatory bodies.

This book constitutes a fascinating and in-depth analysis of the significance of the requirement of industrial application within gene patenting and how this influences innovation in Europe and the US. The author addresses an area normally overlooked in biotechnology patenting due to the predominance of the ethical debate and, in doing so, produces a unique approach to dealing with concerns in this field. Patenting Genes: The Requirement of Industrial Application is the result of extensive research into the legal history of the industrial application requirement as well as exploration of the broad range of decisions on DNA patentability. This requirement has taken a prominent role within DNA patenting decisions in Europe since the 1998 Biotech Directive, which Dr Diaz Pozo argues has worked efficiently to control claims to human gene sequences and encouraged progress in genetic research. A broad selection of decisions on the patentability of DNA in both European Union and US courts is discussed, emphasizing the mirroring of the European approach in US cases. Academics and students of patent law and biotechnology innovation, as well as policy formulators, will find this book of great interest and value. Activists and practitioners interested in the patentability of human gene inventions in Europe and the US will also benefit from this original work.

For undergraduate and graduate courses on marketing high-tech products Provide your students with the vital information they need to successfully market high-tech products. Marketing of High-Technology Products and Innovations is the only text on the market that focuses on the unique marketing challenges that surround high-tech products and service. The third edition retains all the same concepts and materials of previous editions and includes comprehensive coverage of the latest academic research and leading-edge business practices.

The development of biotechnological innovations is quickly becoming a globalized phenomenon as emerging nations are making major strides to compete with more developed economies. Though efforts to bridge the gap between emerging and developed nations have been successful, there are still many barriers that need to be overcome. Comparative Approaches to Biotechnology Development and Use in Developed and Emerging Nations evaluates the importance of manufacturing biotechnological products around the world. Highlighting a comparative analysis of public policies, technological policies, innovations, and marketing capabilities of developed and emerging nations, this publication is a pivotal reference source for government officers, policy makers, academics, and practitioners.

Innovation is the translation of a new method, idea, or product into reality and profit. It is a process of connected steps that accumulates into your brand or reputation. However, there can be many pitfalls and wrong turns on the road to realizing this goal. Innovation, Commercialization, and Start-Ups in Life Sciences details the methodologies necessary to create a successful life sciences start-up from initiation to exit. You will gain an appreciation for the necessary data, partnership, and skills to be acquired and the constituencies that must be satisfied along the way. The book examines how life sciences start-ups can create an exit for their investors by recognizing that a liquidity event is not consummated without due diligence. Due diligence is bigger than validating accounting transactions. It ensures the company is solving an important customer problem, demonstrating sales access, and making sure that intellectual property is impervious to competitive advancement. The due diligence process supports the telling of a compelling story to customers, investors, regulators, and acquirers. Written by an expert who has worked with more than 200 life sciences start-ups during the past decade, the book discusses specific processes and investor milestones that must be navigated to align customer, funder, and acquirer needs. It examines these processes from the perspective of marketing value through a focus on the needs of individual constituents-investors, regulators, customers, and exit candidates. The book presents data and analytical processes articulating the fundable milestones for angel and venture capital. It gives you the tools needed to create branding for public investors and more.

From analyzing competition and identifying market segments, to capitalizing on Internet marketing opportunities and creating valuable after-sale services, this practical text aims to help the reader to apply marketing principles to foster success in the international market-place. It teaches how to objectively evaluate and manage their company's technological and knowledge-based competencies, develop effective product and pricing strategies, more precisely target their marketing efforts and utilize up-to-date distribution and sales channels. Also included is an investigation into the most effective positioning of the marketing department within the organization and a step-by-step guide to writing a strategic marketing plan.

Founded in 1987 by a former engineer in China's People's Liberation Army (Ren Zhengfei), Huawei Technologies is the world's largest telecoms equipment manufacturer and second only to Apple in smartphones. Its emergence into a multinational with over 175,000 employees all around the world is nothing short of extraordinary. This book delves into the financial workings and systems within Huawei - and the individuals whose craftsmanship and excellence enabled Huawei to expand globally in such impressive terms. Their personal stories tell us about the extraordinary vision, dedication, and perseverance required for companies to establish a robust financial system that supports the growth of a world-class company. Huawei's goal is not just to have profitable income and healthy cash flow. More important is that operating results are sustainable.

"The semiconductor industry is at the forefront of current tensions over international trade and investment in high technology industries. This book traces the struggle between U.S. and Japanese semiconductor producers from its origins in the 1950s to the novel experiment with ""managed trade"" embodied in the U.S.-Japan Semiconductor Trade Arrangements of 1986, and the current debate over continuation of elements of that agreement. Flamm provides a thorough analysis of this experiment and its consequences for U.S. semiconductor producers and users, and presents extensive discussion of patterns of competition within the semiconductor industry. Using a wealth of new data, he argues that a fundamentally new trade regime for high technology industries is needed to escape from the present impasse. He lays out the alternatives, from laissez-faire to managed trade, and argues strongly for a new set of international ground rules to regulate acceptable behavior by government and firms in high-tech industries. Flamm's detailed analysis of competition within the semiconductor industry will be of great value to those interested in the industrial organization of high-technology industries, as well as those concerned with trade and technology policy, international competition, and Japanese industrial policies. "

Based on in-depth study of the electronics giant Philips, Corporate Strategy, Public
Policy and New Technologies examines the key factors which have determined the
success or failure of new technologies and the global competitiveness of firms within a major
European consumer industry. Drawing on the insights gained from intensive empirical
research into the company's growth, structure and competitive strategy, the book traces the
reciprocal influences of Philips and of European Community policymaking on each other and
on the development of the industry since the 1970s.

The core of the book focuses on
detailed case studies of three major technological initiatives, and analyses the reasons for
their success or failure: the European VCR (Video Cassette Recorder) industry and Philips'
VCR 2000 format; Philips and the development of the European HDTV (High Definition
Television) system; and Philips' CD-i (Compact Disc-interactive) project. All three studies
raise important issues of competition, collaboration, technology and the role of public policy,
with a firm theoretical grounding in the most relevant and up-to-date academic
research.

In addition to providing an instructive analysis of the performance of an industry
at the levels of the firm, the state and the European Community, the book emphasises that the
strategies and policies discussed were adopted largely in response to the global challenge
from the USA and, above all, Japan.

Professor Stazi's volume on biotechnological inventions is an excellent work that any scholar or practitioner in this complex area of law should not only read, but also frequently consult. This detailed, systematic and comprehensive explanation of the provisions on 'patentability of life' - both in the EU and the USA - is combined with the related theories and constructions as well as the relevant case law. In this regard, the author offers a balanced overview of the relevant provisions and their explicit or implied exceptions.' - Alberto Musso, University of Bologna, Italy'The appropriate protection of biotechnological inventions and the so-called 'patentability of life' are one of the most crucial questions of modern intellectual property. It is also one of the most debated, as it involves not only complex legal issues but raises high social, ethical and even sometimes religious concerns. Professor Stazi's book is thus a very timely contribution, managing the 'tour de force' of combining serious and comparative doctrinal analysis of the criteria (and the limits) of patentability, while at the same time offering a good overview of the challenges with regard to bioethics and fundamental rights. Without any doubt, this volume will enrich the already excellent series on New Directions in Patent Law.' - Christophe Geiger, CEIPI, University of Strasbourg, France In today's technological world, biotechnology is one of the most innovative and highly invested-in industries for research, in the field of science. This book analyzes the forms and limitations of patent protection recognition for biotechnological inventions, with particular regard to patentability of life. The author expertly compares the United States model, traditionally based on technical evaluations, with the European model, inspired by fundamental rights and bioethics. He highlights how the regulation of biotechnological inventions should guarantee a fair balance between protection of investment and access to information, which is essential for further research and innovation. Academics and practitioners dealing with intellectual property, patent law and biotechnological inventions will find this book to be of interest. The topics discussed will also be useful for patent offices and medical institutions, as well as medical researchers.

Over the last two decades one of the great global emerging technological trends has been the shift from chemistry to biology in agriculture. Bitterly contested and enduringly controversial, the shift to biotechnology has nevertheless led to greater sustainability and promises even greater gains in years to come. This Handbook is an invaluable compendium of detailed case study and insight.' - Mark Lynas, Cornell University, US'This important volume analyses the current state of crop biotechnology development and regulation. It establishes a firm basis for understanding the current level of deployment of crops modified by biotechnology and also the uneven and often unscientific bases that have been used to judge their merits for particular regions. This book is an indispensable reference for anyone concerned with the development of this vital area of agriculture.' - Peter H. Raven, Missouri Botanical Garden, US 'With interest in biotechnology surging, this book is a must-read for anyone who wants to learn more about the potential that advancements in modern agriculture have to offer, how they've already changed agriculture around the world and what s coming down the pipeline. Agriculture is about economics, the environment and feeding the world; so too, at the heart of it, is biotechnology, as this book so clearly demonstrates. The authors have years of experience with biotechnology and their expertise shines through on each page.' - Lorne Hepworth, CropLife Canada This book is a compendium of knowledge, experience and insight on agriculture, biotechnology and development. Beginning with an account of GM crop adoptions and attitudes towards them, the book assesses numerous crucial processes, concluding with detailed insights into GM products. Drawing on expert perspectives of leading authors from 57 different institutions in 16 countries, it provides a unique, global overview of agbiotech following 20 years of adoption. Many consider GM crops the most rapid agricultural innovation adopted in the history of agriculture. This book provides insights as to why the adoption has occurred globally at such a rapid rate. This is a rich and varied collection of research, which will appeal to scholars, academics and practitioners worldwide. An invaluable resource, this book will be a first point of reference to anyone with an interest in agbiotech and studies into agriculture, biotechnology and development. Contributors: A.A. Adenle, P. Aerni, C. Alexander, J.M. Alston, V. Beckmann, J. Bognar, C.G. Borroto, D. Brewin, G. Brookes, J. Carpenter, Y. Carriere, D. Castle, M. Chen, P. Conceicao, B. Dayananda, M. Demont, K. Dillen, D. Eaton, E. Einsiedel, J. Falck-Zepeda, J. Fernandez-Cornejo, G.B. Frisvold, C.V. Gonslaves, D. Gonsalves, M. Gouse, G. Graff, R. Gray, A. Gupta, W.O. Hennessey, J.E. Hobbs, W.E. Huffman, L. A. Jackson, C. Juma, N. Kalaitzandonakes, S. Kaplan, V.J. Karplus, W.A. Kerr, G.G. Khachatourians, E.M. Kikulwe, E. Kim, D.E. Kolady, S.P. Kowalski, J. Kruse, L. Levidow, S. Levine, K. Ludlow, X. Ma, A. Magnier, S. Malla, I. Matuschke, J.J. McCluskey, A. McHughen, J. Medlock, D. Miller, L. Nagarajan, A. Naseem, C. Oguamanam, M. Ouattarra, M. Owen, R. Paarlberg, P. W. B. Phillips, M. Qaim, T. Raney, J.M. Reeves, S.D. Rhodes, S.M.H. Rizvi, C.D. Ryan, D. Schimmelpfennig, G.J. Scoles, G. Skogstad, S. J. Smyth, C. Soregaroli, D.J. Spielman, A.J. Stein, J. Thomson, J. Vitale, G. Vognan, G. Waterfield, S. Wechsler, J. Wesseler, A. Williams, W.W. Wilson, L.L. Wolfenbarger, G. Ye, J. Yorobe Jr, D.Z. Zeng, D. Zilberman

Video recording has recently become an important phenomenon. Although the majority of American homes have at least one video recording set, not much is known about video recording's past and about its continual effect on affiliated industries. This text documents the history of magnetic recording, stressing its importance in consumer as well as commercial applications from the advent of magnetism through the invention of such new technologies as Digital Audio Tape (DAT), High Definition Television (HDTV), and a multitude of sophisicated Digital Video Cassette Recorders.

The new millennium has carried several challenges for patent law. This up-to-date book provides readers with an important overview of the most critical issues patent law is still facing today at the beginning of the twenty first century, on both sides of the Atlantic. New technological sectors have emerged, each one with its own features with regard to innovation process and pace. From the most controversial cases in biotech to the most recent decisions in the field of software and business methods patent, patent law has tried to stretch its boundaries in a way to accommodate such new and controversial subject matters into its realm. Biotechnology and Software Patent Law will strongly appeal to postgraduate students specializing in IP law, international law, commercial and business law, competition law as well as IP scholars, academics and lawyers. Contributors: S.D. Anderman, R.B. Bakels, S.J.R. Bostyn, D.L. Burk, V. Di Cataldo, V. Falce, C. Geiger, R.M. Hilty, C.M. Holman, M.A. Lemley, A. Ottolia, J. Pila, J.R. Thomas, P.L.C. Torremans

This book provides a clear analysis of the multi-level impacts of the existing international law regime related to genetic resources on developing countries. It does so through a cogent exposition of the different areas of the law pertaining to genetic resources that are relevant and impact on people's rights and livelihoods. Its focus on equity is a welcome addition to the literature.' - Philippe Cullet, University of London, UK'Camena Guneratne's thought-provoking book critically evaluates the clash between the private property approach to genetic resources embedded in international intellectual property conventions, and the competing values embedded in a variety of other conventions and laws. She contests key assumptions behind intellectual property regimes supporting genetic commerce, distinguishing the genetic 'commons' from other types of resource. This book provides a comprehensive scholarly dealing with the topics noted in its title, but also should increase debate about policy failures in responding to the risks to the underprivileged of the instruments we use to pursue our economic interests of the majority.' - Paul Martin, University of New England, Australia 'This is a wonderful book. All to often in the quest to preserve biodiviersity, we forget that the equation of equity hs to be the forefront of the debates on sustainable development. Dr. Guneratne rectifies this mistake.This linkage between biodiversity, politics and international law is of such a high calibre, that it is likely that this work will become a key text for students and scholars alike.' - Alexander Gillespie, University of Waikato, New Zealand This book examines current developments in international law which regulate the uses of plant genetic resources for food and agriculture, and the various property regimes which are applied to these resources by these international agreements. In the current context of the global food crisis, the development and stability of national agricultural systems is an urgent concern, particularly among developing countries. This stability, and national food security, will potentially be threatened if these countries are unable to have free access to agricultural crop plants. This book analyses a range of international agreements including the recently adopted Nagoya Protocol and demonstrates that in their current implementation they favor private ownership of these resources rather than free access. The book takes the position that this is inherently inequitable and these resources should be maintained in the public domain. This book will be of use to a wide range of readers from students and scholars to those working in the fields of trade and intellectual property, human rights, environmental conservation and advocacy on international issues. It contains a rigorous legal analysis of current international law development on the issue based on the negotiations which have taken place in the relevant forums, and will therefore be particularly useful to lawyers and legal scholars. It is also written in an uncomplicated style which makes it readily accessible to non-lawyers and the case studies and empirical data used throughout the book adds to its interest.

Key Account Management Excellence in Pharma & Medtech is designed to help life sciences practitioners develop and execute innovative and effective key account management (KAM) strategies and capabilities. Pharmaceutical and medtech companies are increasingly pursuing KAM in response to the rapid rise of large, sophisticated and complex healthcare provider and payer systems and groups. Those that invest the time to get KAM right will protect their business and grow with these rising customers. This book is groundbreaking in both its scope and its tailoring of leading KAM practices specifically for life sciences. The central theme is that "key account management is an organization-wide business strategy, not just a role or a sales-specific initiative." KAM is a strategy focused on providing unique offerings and value through an orchestrated, cross-functional, go-to-market model designed specifically to address the needs and engagement preferences of a unique segment of customers. The insights and practices shared in this book are designed to be a valuable reference at every stage of the KAM journey. The book has been designed to facilitate a common language and deep understanding of KAM issues and leading practices organization-wide-particularly for life sciences leaders, account managers and cross-functional team members responsible for building, transforming and supporting their organization's KAM strategies and capabilities.

This is an original and very well structured and informative book. Its particular interest stems from the multidimensional and detailed analysis of a set of core technologies and their uneven diffusion process in eight countries of quite different levels of development. It challenges received ideas about what really matters to democratize the access to new technologies and provides evidence-based suggestions for policy design. Scholars and students interested in the technological side of inequality will read this book with delight.' - Judith Sutz, Universidad de la Republica, UruguayInequality is one of the main features of globalization. Do emerging technologies, as they spread around the world, contribute to more inequality or less? This unique interdisciplinary text examines the relationships between emerging technologies and social, economic and other forms of inequality. Susan Cozzens, Dhanaraj Thakur, and the other co-authors ask how the benefits and costs of emerging technologies are distributed amongst different countries - some rich and some poor. Examining the case studies of five technologies across eight countries in Africa, Europe and the Americas, the book finds that the distributional dynamics around a given technology are influenced by the way entrepreneurs and others package the technology, how governments promote it and the existing local skills and capacity to use it. These factors create social and economic boundaries where the technology stops diffusing between and within countries. The book presents a series of recommendations for policy-makers and private sector actors to move emerging technologies beyond these boundaries and improve their distributional outcomes. Offering a broad range of mature and relatively new emerging technologies from a diverse set of countries, the study will strongly appeal to policy-makers in science, technology and innovation policy. It will also benefit students and academics interested in innovation, science, technology and innovation policy, the economics of innovation, as well as the history and sociology of technology. Contributors: B. Beckert, I. Bortagaray, L. Brito, R. Brouwer, S. Cozzens, M.P.Falcao, S.D. Gatchair, J.A. Holbrook, L.A. Pace, D. Thakur

A new era of space-based technology and interplanetary exploration will produce cost-effective solutions and innovative technologies to fulfill current societal needs. Space-Based Technologies and Commercialized Development: Economic Implications and Benefits introduces the concept of space-based technology commercialization and offers a first-time analysis of plausible opportunities. This essential reference examines the overall marketability of tourism in outer space, including business case studies on celestial solar power and space debris that demonstrate the potential of cosmic technologies in the context of interplanetary business.

Key Account Management Excellence in Pharma & Medtech is designed to help life sciences practitioners develop and execute innovative and effective key account management (KAM) strategies and capabilities. Pharmaceutical and medtech companies are increasingly pursuing KAM in response to the rapid rise of large, sophisticated and complex healthcare provider and payer systems and groups. Those that invest the time to get KAM right will protect their business and grow with these rising customers. This book is groundbreaking in both its scope and its tailoring of leading KAM practices specifically for life sciences. The central theme is that "key account management is an organization-wide business strategy, not just a role or a sales-specific initiative." KAM is a strategy focused on providing unique offerings and value through an orchestrated, cross-functional, go-to-market model designed specifically to address the needs and engagement preferences of a unique segment of customers. The insights and practices shared in this book are designed to be a valuable reference at every stage of the KAM journey. The book has been designed to facilitate a common language and deep understanding of KAM issues and leading practices organization-wide-particularly for life sciences leaders, account managers and cross-functional team members responsible for building, transforming and supporting their organization's KAM strategies and capabilities.

The Future of Work in Asia and Beyond presents the findings and associated implications arising from a collaborative research study conducted on the potential impact of the Fourth Industrial Revolution (4IR - or Industry 4.0) on the labour markets, occupations and associated future workforce competencies and skills across ten countries. The 4IR concerns the digital transformation in society and business - an interface between technologies in the physical, digital and biological disciplines. The book explores many related issues: the nature of the 4IR, as well as demographic, generational and socio-cultural issues, economic and political perspectives, public and private sector similarities and differences, business strategy and managerial implications, human resource management/planning strategies, policies and practices, industry innovations, 'best practice' cases and comparative country studies. Chapters are based on a framework which combines labour market and multiple stakeholder theories. Issues are explored through the perceptions of organisational managers based in Australia, China, India, Indonesia, Malaysia, Mauritius, Nepal, Singapore, Taiwan and Thailand to provide an analysis of organisational, industry and government preparedness for the 4IR. This book is recommended reading for anyone wanting to gain an understanding of the 4IR and a range of related challenges and issues, as well as suggested strategies for governments, education and industry that are necessary to address them.

* Focus on seven critical, fast-paced industries where innovation capability is essential * Written by two prominent thought leaders with 50 years of combined experience working with hundreds of companies across industries * Provides templates to immediately put the book's frameworks in place to develop an organization's innovation plan

In the year 2000, European Union governments announced a long-term strategic commitment to transform the European economy into the most competitive, dynamic, knowledge-based economy in the world. Technology is an integral part of the new economy and of the EU's strategy for economic development. This book deals with the development of infrastructure in the mobile communications, transport, space and radio sectors. It sets out to explain the conditions under which the EU, and in particular the European Commission, makes policy choices to support large-scale technology infrastructures, and why EU political intervention in seemingly similar infrastructure projects varies. Answering this question will provide insights into the political economy underpinning the ambitions to transform the European economy into the most competitive in the world. This study of EU political intervention in support of advanced technology will be a fascinating read for advanced students and academic researchers of international political economy, international affairs and political science. Competition for Technological Leadership will also appeal to journalists, policymakers and analysts with a special interest in EU high technology policy.

This book is an everything-included approach to understanding drones, creating an organization around using unmanned aircraft, and outlining the process of safety to protect that program. It is the first-of-a-kind safety-focused text book for unmanned aircraft operations, providing the reader with a required understanding of hazard identification, risk analysis, mitigation, and promotion. It enables the reader to speak the same language as any civil aviation authority, and gives them the toolset to create a safety risk management program for unmanned aircraft. The main items in this book break down into three categories. The first approach is understanding how the drone landscape has evolved over the last 40 years. From understanding the military components of UAS to the standards and regulations evolution, the reader garners a keen understanding of where we came from and why it matters for moving forward. The second approach is in understanding how safety risk management in aviation can be applied to drones, and how that fits into the regulatory and legislative environment internationally. Lastly, a brief synopsis of the community landscape for unmanned aircraft is outlined with interviews from important leaders and stakeholders in the marketplace. Drones fills a gap in resources within the unmanned aircraft world. It provides a robust understanding of drones, while giving the tools necessary to apply for a certificate of authorization, enabling more advanced flight operations for any company, and developing safety risk management tools for students and career professionals. It will be a mainstay in all safety program courses and will be a required tool for any and all individuals looking to operate safely and successfully in the United States.